Loading
Kura Oncology, Inc. Stock: price and insider trades · United States
1 insider bought €2.0M of shares over the last 90 days, the latest by WILSON TROY EDWARD, filed 24 Aug 2026.
Insider Decl.
222
Thresholds
n/a
Buy Volume
€8M
14 ops. · all time
Sell Volume
€22M
106 ops. · all time
Who traded when
BuySaleMollie Leoni12 sales
Thomas James Doyle12 sales
Teresa Brophy Bair10 sales
Brian T. Powl9 sales
Kathleen Ford8 sales
Troy Edward Wilson5 buys1 sale
+2 other insiders
Since the insiders bought
- -26.6%Entry US$13.59 · Close 20 Oct 2026 US$9.98
- +92.8%Entry US$10.86 · Close at T+365 US$20.94
- -21.8%Entry US$16.76 · Close at T+365 US$13.10
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Kura Oncology, Inc. Strong Buy (bullish), based on 13 analysts. Average price target: US$31.85.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 20,804 of 26,248 companies
31.3
score / 100
Value13
Quality50
FCF yld-8.5%
Earn yld-33%
EV/EBITDA·
ROE-168%
Gross mgn100%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$9.36
Analyst consensus
13 analystsStrong buy
US$15.00Target US$31.85(+240%)US$76.00
Income statement
RevenueUS$67.5M
Gross profitUS$67.4M100% margin
EBITDA-US$275.8M-409% margin
Net income-US$278.7M-412.9% margin
Valuation
PER (forward)-4.0x
P/Book17.2x
Beta0.47
Balance sheet & cash
Market capUS$832.7M
Total debtUS$20.5M
Free Cash Flow-US$70.7M
Debt / Equity50%
Profitability & ownership
ROE-167.7%
ROA-31.3%
% insiders1.4%
% institutions100.2%
Last declaration on 29 September 2026
Declarations222 total
3,668 shares@ US$10.610.0040% mcap100.0% of flowCommonSEC144:0001950047-26-009864
28,802 shares@ US$10.610.032% mcap100.0% of flowCommonSEC144:0001950047-26-009865
15,430 shares@ US$10.610.017% mcap65.6% of flowCommonSEC144:0001950047-26-009866
6,906 shares@ US$10.49730.0075% mcap25.0% of flowCommon StockSEC:0001193125-26-407938:0
8,000 shares@ US$10.56220.0088% mcap18.8% of flowCommon StockSEC:0001193125-26-407935:1
15,430 shares@ US$10.74870.017% mcap37.0% of flowCommon StockSEC:0001193125-26-407935:2
8,442 shares@ US$10.49730.0092% mcap12.3% of flowCommon StockSEC:0001193125-26-407939:0
12,448 shares@ US$10.49730.014% mcap26.7% of flowCommon StockSEC:0001193125-26-407937:0
3,668 shares@ US$10.75160.0041% mcap13.6% of flowCommon StockSEC:0001193125-26-407938:1
9,020 shares@ US$10.49730.0099% mcap21.1% of flowCommon StockSEC:0001193125-26-407935:0
28,802 shares@ US$10.74810.032% mcap63.3% of flowCommon StockSEC:0001193125-26-407937:1
4,607 shares@ US$10.49720.0050% mcap31.0% of flowCommon StockSEC:0001193125-26-407936:0
8,442 shares@ US$10.760.0095% mcap100.0% of flowCommon StockSEC144:0001193125-26-405712
4,607 shares@ US$10.760.0052% mcap46.0% of flowCommon StockSEC144:0001193125-26-405710
6,906 shares@ US$10.760.0078% mcap41.7% of flowCommon StockSEC144:0001193125-26-405713
12,448 shares@ US$10.760.014% mcap100.0% of flowCommon StockSEC144:0001193125-26-405711
9,020 shares@ US$10.760.010% mcap100.0% of flowCommon StockSEC144:0001193125-26-405751
8,000 shares@ US$10.760.0090% mcap100.0% of flowCommonSEC144:0001950047-26-009845
20,726 shares@ US$10.83250.027% mcap38.1% of flowCommon StockSEC:0001193125-26-402815:1
30,000 shares@ US$6.150.023% mcap31.3% of flowCommon StockSEC:0001193125-26-402815:0
20,726 shares@ US$10.83250.027% mcap100.0% of flowCommonSEC144:0001950047-26-009786
4,345 shares@ US$11.89030.0052% mcap48.8% of flowCommon StockSEC:0001193125-26-363810:0
100,000 shares@ US$12.390.12% mcap40.6% of flowCommon StockSEC:0001193125-26-363812:0
Canonical exit: 22 Nov 2026 (T+90)
4,345 shares@ US$11.710.0050% mcap100.0% of flowCommonSEC144:0001950047-26-008548
31,487 shares@ US$12.630.040% mcap62.0% of flowCommon StockSEC:0001193125-26-361184:0
25 of 222 declarations
About Kura Oncology, Inc.
Troy Edward Wilson, President and CEO of Kura Oncology, Inc., appears on both sides of the record. The three largest sales date from autumn 2020: EUR 3,084,068 on October 8, EUR 2,716,641 on October 7 and EUR 2,391,307 on September 14. In August 2026, Troy Edward Wilson bought EUR 1,060,708 on August 24 and EUR 959,990 on August 17, the two largest purchases in the record. Troy Edward Wilson files 66 of the 222 filings, of which 5 purchases and 20 sales.
In all, 106 sales worth EUR 22.3 million (median EUR 48,897) and 14 purchases worth EUR 7.6 million (median EUR 559,378), so 12% of open-market trades are purchases. EcoR1 Capital Fund Qualified, L.P., 10% Owner, bought EUR 959,588 on December 21, 2018.
Read moreShow less
Kathleen Ford, Chief Operating Officer, files 26, of which 16 sales, and Teresa Brophy Bair, Chief Legal Officer, 19, of which 13 sales. Annual volume reaches 51 in 2020 and 51 in 2026. The last twelve months hold 66 filings, of which 2 purchases and 35 sales. The US healthcare and pharma company is worth USD 832.7 million, with 1.4% of the shares held by insiders. For 12 purchases, the stored 90-day median is 8.4%, with 67% of results positive (recorded past, not a forecast).
